$11 billion biotech binge fuels forecasts of 2018 M&A surge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Speculative Bullish Options Activity in Gilead Sciences (GILD) Targets Multiple Potential Catalysts, Including Feb. 12 PDUFA Date for Bictegravir -Susquehanna
January 9, 2018 1:58 PM ESTSusquehanna options strategist Allison Edwards notes speculative bullish options activity in Gilead Sciences (NASDAQ: GILD), as opening investors purchased14k May 90 Calls for $0.91. The May options capture multiple potential catalysts, including a Feb 12th PDUFA date for Bictegravir drug.
... MoreGilead Sciences (GILD) PT Maintained at $83 at JPMorgan on Update from JP Morgan Healthcare Conference
January 9, 2018 6:09 AM ESTJPMorgan maintained its price target on Gilead Sciences (NASDAQ: GILD) at $83.00 while maintaining a Overweight rating, following comments from management at the J.P. Morgan Healthcare Conference.
Analyst Cory Kasimov provides a quick update to investors from inside the J.P. Morgan Healthcare... More
